Bristol Price to Earning Trend from 2010 to 2020

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

Bristol Myers Consolidated Income is fairly stable at the moment as compared to the last year. Bristol Myers reported Consolidated Income of 3.46 Billion in 2019. Net Income is likely to grow to about 6.2 B in 2020, whereas Direct Expenses is likely to drop slightly above 6.5 B in 2020.

Search Historical Trends

 
Refresh
Check Bristol Myers financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 6.5 B, Consolidated Income of 3.5 B or Cost of Revenue of 7.3 B, as well as many exotic indicators such as Interest Coverage of 9.25, Long Term Debt to Equity of 0.9072 or Calculated Tax Rate of 26.35. This can be a perfect complement to check Bristol Myers Valuation or Volatility. It can also complement various Bristol Myers Technical models. Continue to the analysis of Bristol Myers Correlation with competitors.

Bristol Price to Earning Marginal Breakdown

Showing smoothed Price to Earnings Ratio of Bristol Myers Squibb with missing and latest data points interpolated. An alternative to [PE] representing the ratio between [Price] and [EPSUSD].
View

13.19 

          10 Years Trend
 Price to Earnings Ratio 
      Timeline 

Bristol Price to Earning Regression Statistics

Arithmetic Mean 35.40
Geometric Mean 26.27
Coefficient Of Variation 81.03
Mean Deviation 21.13
Median 27.86
Standard Deviation 28.68
Sample Variance 822.69
Range 95.74
R-Value 0.19
Mean Square Error 881.76
R-Squared 0.035374
Significance 0.58
Slope 1.63
Total Sum of Squares 8,227

Bristol Price to Earning Over Time

2010  4.72 
2011  16.17 
2012  27.86 
2013  34.07 
2014  48.79 
2015  73.18 
2016  21.89 
2017  100.46 
2018  17.27 
2019  31.78 
2020  13.19 

About Bristol Myers Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Bristol Myers investors use historical funamental indicators, such as Bristol Myers's Price to Earning, to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol Myers Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 30000 people.

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb. What is your opinion about investing in Bristol Myers Squibb? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Astrazeneca PLC. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Bristol Myers Correlation with competitors. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page